2
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 1
1
Status
Completed
2
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Genitourinary
2
Conditions
Carcinoma, Transitional Cell
29
Carcinoma, Non-Small-Cell Lung
29
Urinary Bladder Neoplasms
26
Neoplasms
22
Carcinoma, Renal Cell
22
Carcinoma, Merkel Cell
21
Neoplasm Metastasis
18
Colorectal Neoplasms
16
Breast Neoplasms
16
Squamous Cell Carcinoma of Head and Neck
15
Ovarian Neoplasms
14
Triple Negative Breast Neoplasms
11
Pancreatic Neoplasms
9
Melanoma
9
Head and Neck Neoplasms
8
Stomach Neoplasms
7
Recurrence
6
Carcinoma, Hepatocellular
6
Ureteral Neoplasms
5
Small Cell Lung Carcinoma
5
Prostatic Neoplasms
5
Urethral Neoplasms
4
Sarcoma
4
Neuroendocrine Tumors
4
Leukemia, Myeloid, Acute
4
Glioblastoma
4
Carcinoma, Squamous Cell
4
Uterine Cervical Neoplasms
3
Turcot syndrome
3
Skin Neoplasms
3
Interventions
Sunitinib
4
avelumab
2
Nutrition Assessment
2
Blood Specimen Collection
2
Axitinib
2
trifluridine tipiracil drug combination
1
trebananib
1
spartalizumab
1
pembrolizumab
1
palbociclib
1
etelcalcetide hydrochloride
1
enzalutamide
1
cabozantinib
1
bicalutamide
1
atezolizumab
1
aldesleukin
1
Valsartan
1
VMBP protocol
1
Stents
1
Specimen Handling
1
Sorafenib
1
Sodium Bicarbonate
1
Resistance Training
1
Receptors, Androgen
1
Plasma Exchange
1
Pharmaceutical Preparations
1
Paclitaxel
1
Oxaliplatin
1
Nivolumab
1
Nephrotomy
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Kidney Diseases
×
avelumab
×
Clear all
NCT02684006
2025-07-30
JAVELIN Renal 101
Pfizer
Phase 3
Completed
886 enrolled
37 charts
1 FDA
NCT02493751
2022-02-18
JAVELIN Renal 100
Pfizer
Phase 1
Completed
55 enrolled
27 charts